

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number  
**WO 03/079020 A2**

- (51) International Patent Classification<sup>7</sup>: G01N 33/574, 33/68, A61K 45/00 (74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (21) International Application Number: PCT/EP03/02916 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (22) International Filing Date: 20 March 2003 (20.03.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/366,370 20 March 2002 (20.03.2002) US (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).
- (71) Applicant (*for all designated States except TM, US*): DANA-FARBER CANCER INSTITUTE INC. [US/US]; 44 Binney Street, Boston, MA 02115 (US).
- Published:  
— without international search report and to be republished upon receipt of that report
- (71) Applicant (*for TM only*): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): SALGIA, Ravi [US/US]; 17 Michael Drive, Burlington, MA 01803 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 03/079020 A2

(54) Title: METHODS AND COMPOSITIONS FOR THE IDENTIFICATION, ASSESSMENT, AND THERAPY OF SMALL CELL LUNG CANCER

(57) Abstract: The invention provides novel methods and compositions for modulating small cell lung cancer (SCLC) proliferation and metastasis through modulation of CXCR4 activity or expression. Also provided are methods for identifying compounds that modulate SCLC proliferation and metastasis through modulation of CXCR4 activity or expression. Further provided are methods for treating SCLC proliferation and metastasis, as well as methods for determining whether subjects are suitable candidates for treatment of SCLC via modulation of CXCR4 activity.

(19) 日本国特許庁 (JP)

(12) 公表特

|                            |         |
|----------------------------|---------|
| (51) Int. Cl. <sup>7</sup> | F 1     |
| A 6 1 K 45/00              | A 6 1 K |
| A 6 1 K 31/7088            | A 6 1 K |
| A 6 1 K 39/395             | A 6 1 K |
| A 6 1 K 48/00              | A 6 1 K |
| A 6 1 P 35/00              | A 6 1 K |
|                            | 審査請求    |

|               |                              |
|---------------|------------------------------|
| (21) 出願番号     | 特願2003-576974 (P2003-576974) |
| (86) (22) 出願日 | 平成15年3月20日 (2003. 3. 20)     |
| (85) 翻訳文提出日   | 平成16年11月19日 (2004. 11. 19)   |
| (86) 国際出願番号   | PCT/EP2003/002916            |
| (87) 国際公開番号   | W02003/079020                |
| (87) 国際公開日    | 平成15年9月25日 (2003. 9. 25)     |
| (31) 優先権主張番号  | 60/366, 370                  |
| (32) 優先日      | 平成14年3月20日 (2002. 3. 20)     |
| (33) 優先権主張国   | 米国 (US)                      |







.....

















.....  
.....















































































































---